Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
HNRNPU Lactylation in Cervical Cancer Metabolism
2026-11-16
A literature-focused analysis of how HNRNPU K181 lactylation may connect lactate accumulation with PHGDH regulation, serine metabolism, and cervical cancer growth, while separating the study’s pharmacological evidence from the distinct proteasome-control role of (R)-MG132.
When Context Changes a Molecular Result
2026-11-16
A cervical-cancer study links HNRNPU K181 lactylation to PHGDH expression, serine metabolism and tumor growth, but each result supports a different level of inference. The contrasting role of (R)-MG132 as a stereoisomeric proteasome control shows why material identity, comparator choice, model and readout must remain connected.
What (R)-MG132 Can—and Cannot—Show
2026-11-15
The cervical-cancer study supports a lactate-responsive HNRNPU K181–PHGDH axis that connects post-translational regulation with serine metabolism and tumor growth. (R)-MG132 has a different evidentiary role: as a low-activity stereoisomeric proteasome control, it can help separate proteasome-dependent effects from the lactylation mechanism, but it cannot establish that mechanism itself.
CCR7–Notch1 Crosstalk in Mammary Cancer Stemness
2026-11-14
Boyle et al. used genetic, pharmacological, molecular and functional readouts in an MMTV-PyMT mouse model to investigate how CCR7 signaling intersects with Notch1 in mammary cancer stem-like cells. The findings support a context-dependent signaling relationship, while leaving clinical causality, therapeutic efficacy and broader applicability unresolved.
When Context Changes a Biological Result
2026-11-13
A cervical-cancer study illustrates how model, perturbation, comparator, and readout determine what a molecular result can mean. The associated (R)-MG132 material has a distinct control role in proteasome research and should not be treated as evidence for the reported lactylation mechanism.
HNRNPU Lactylation and the Role of (R)-MG132
2026-11-13
A 2026 study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine metabolism, and cervical cancer growth. Its findings also clarify why (R)-MG132 should be interpreted as a low-activity proteasome-control compound rather than as the causal perturbation underlying this pathway.
HNRNPU Lactylation and (R)-MG132
2026-11-12
The cervical-cancer study supports a lactate–HNRNPU–PHGDH axis, but it does not establish (R)-MG132 as a causal probe of that mechanism. This editorial distinguishes the study’s evidence for post-translational regulation and serine metabolism from the separate role of the MG-132 enantiomer as a low-activity proteasome-control compound.
HNRNPU Lactylation and (R)-MG132 Control
2026-11-12
A cervical-cancer study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine metabolism, and tumor growth. (R)-MG132 is best interpreted as a proteasome-control material that can frame protein-turnover questions, not as the pharmacological basis of the reported metabolic mechanism.
What (R)-MG132 Can and Cannot Show
2026-11-11
A source-grounded interpretation of the HNRNPU K181 lactylation study, distinguishing its mechanistic evidence from the separate conceptual role of (R)-MG132 as a low-activity proteasome control.
When Context Changes a Cancer Result
2026-11-11
A cervical-cancer study illustrates how molecular, genetic, pharmacological, and model-specific contexts determine what a result can legitimately mean. It also clarifies why (R)-MG132, an MG-132 enantiomer used as a low-activity proteasome control, belongs to a different evidentiary question than the study’s central lactylation mechanism.
H-89 and Wnt-Driven Bone Metabolism
2026-11-10
The cited study places PKA-linked signaling within a broader Wnt–O-GlcNAcylation–glycolysis pathway that supports osteoblast differentiation and bone formation. H-89 is most informative as a pharmacological probe of the proposed early PKA–GFAT1 branch; the strongest causal evidence came from genetic manipulation and molecular analysis of PDK1 O-GlcNAcylation.
How HNRNPU Lactylation Rewires Cervical Cancer
2026-11-10
A literature-focused analysis of how HNRNPU K181 lactylation was linked to PHGDH expression, serine metabolism, and cervical cancer growth, with separate consideration of the proteasome-control role of (R)-MG132.
When Context Changes What a Result Means
2026-11-09
A cervical-cancer study illustrates why genetic, biochemical and pharmacological contexts give different meanings to similar growth readouts. The discussion also distinguishes the role of (R)-MG132 as a proteasome-control compound from evidence establishing the HNRNPU–PHGDH lactylation mechanism.
Blebbistatin in Panoramic Cardiac Mapping
2026-11-09
A multimodal rat-heart study linked collagen-associated tissue signatures with panoramic optical measurements of membrane potential. (±)-Blebbistatin is best interpreted as a contractility-related measurement-context variable in this work, not as the cause of the infarct-associated electrophysiological patterns.
When Context Changes a Molecular Result
2026-11-08
A cervical-cancer study shows why lactylation, genetic perturbation, drug response, and proteasome controls answer different scientific questions. The meaning of (R)-MG132 is comparative and context-dependent: it can inform proteasome-related interpretation, but it is not evidence for the study’s central HNRNPU–PHGDH mechanism.